INNOVIVA, INC. (INVA) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 72.25M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 72.25M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 72.25M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 72.25M | (m) | (m) |
| 2026-03-31 | 73.81M | (m) | (m) |
| 2025-12-31 | 74.07M | (m) | (m) |
| 2025-09-30 | 74.77M | (m) | (m) |
| 2025-06-30 | 63.02M | (m) | (m) |
| 2025-03-31 | 62.78M | (m) | (m) |
| 2024-12-31 | 62.68M | (m) | (m) |
| 2024-09-30 | 62.60M | (m) | (m) |
| 2024-06-30 | 62.56M | (m) | (m) |
| 2024-03-31 | 62.44M | (m) | (m) |
| 2023-12-31 | 63.23M | (m) | (m) |
| 2023-09-30 | 64.09M | (m) | (m) |
| 2023-06-30 | 65.10M | (m) | (m) |
| 2023-03-31 | 65.50M | (m) | (m) |
| 2022-12-31 | 68.13M | (m) | (m) |
| 2022-09-30 | 69.78M | (m) | (m) |
| 2022-06-30 | 69.71M | (m) | (m) |
| 2022-03-31 | 69.70M | (m) | (m) |
| 2021-12-31 | 69.57M | (m) | (m) |
| 2020-12-31 | 101.39M | (m) | (m) |
| 2019-12-31 | 101.30M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |